Dose-escalation and Dose-expansion Study of Trastuzumab-deruxtecan(T-Dxd) Monotherapy and Combinations in Patients with advanced/metastatic HER2+Gastric Cancer (GC)/Adenocarcinoma of the gastroesophageal Junction (GEJA): DESTINY-Gastric03-MedSci.cn

Dose-escalation and Dose-expansion Study of Trastuzumab-deruxtecan(T-Dxd) Monotherapy and Combinations in Patients with advanced/metastatic HER2+Gastric Cancer (GC)/Adenocarcinoma of the gastroesophageal Junction (GEJA): DESTINY-Gastric03

Lordick, F; Janjigian, YY; Oh, DY; Rha, SY; Lee, KW; Steeghs, N; Chao, Y; Di Bartolomeo, M; Diez, GM; Haj, MN; Stein, A; McAdoo, W; Winter, M; Croydon, E; Lee, J

ONCOLOGY RESEARCH AND TREATMENT, 2022; 45 (SUPPL 2): 222

科室
- - 订阅+
  - 更多科室
工具
服务